We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Protein Risk Predicts Mortality Risk in Heart Failure Patients

By LabMedica International staff writers
Posted on 02 Jan 2024
Image: The new protein risk score demonstrated strong clinical utility for predicting death from heart failure (Photo courtesy of SomaLogic)
Image: The new protein risk score demonstrated strong clinical utility for predicting death from heart failure (Photo courtesy of SomaLogic)

Heart failure (HF) is a complex clinical condition characterized by high mortality rates. Existing methods for assessing the biological complexity of HF and determining clinical strategies are somewhat inadequate. High-throughput proteomics has the potential to enhance risk prediction; however, its practical application in managing HF patients requires robust validation and proven clinical advantages. Now, researchers have developed a new protein risk score that offers improved calibration and the potential to assist healthcare providers in more accurately determining the mortality risk in individuals with HF.

Researchers from the National Institutes of Health (NIH, Bethesda, MD, USA) have developed and validated a protein risk score to stratify mortality risk in persons with heart failure using a community-based cohort of 7,289 plasma proteins in 1,351 patients with HF using the SomaScan Assay from SomaLogic (Boulder, CO, USA). In the development cohort, the team chose 38 unique proteins for inclusion in the protein risk score. This score showed good calibration, was particularly effective at reclassifying mortality risk at the extremes of the risk spectrum, and outperformed traditional clinical models in terms of clinical utility.

The research highlights the significant potential of the clinical utility of large-scale proteomic assays in improving risk prediction in HF. The tool could guide clinicians in identifying patients who may benefit from intensified medication management or those at high risk for adverse events who might need mechanical circulatory support or transplantation. Nonetheless, the predominance of participants of European descent in the study raises questions about the score's applicability across various demographics. Therefore, additional research is essential to assess the score's effectiveness in diverse populations and to establish specific risk thresholds for various medical interventions.

Related Links:
NIH 
SomaLogic

Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Prefilled Tubes
Prefilled 5.0ml Tubes

Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Microbiology

view channel
Image: Graphical Abstract (Emery, J. K., V. Nemidkanam, N. Colon, et al. Journal of Extracellular Vesicles (2026). https://doi.org/10.1002/jev2.70286)

Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori

Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
ADLM